Jazz Pharmaceuticals plc (JAZZ) Jumps Nearly 30% on Strong Q3 and Cancer Drug Trial Progress

Core Insights - Harbor Capital Advisors' Mid Cap Value Fund outperformed the Russell Midcap Value Index in Q4 2025, returning 4.07% compared to the index's 1.42% [1] - The Fund achieved a total return of 15.95% for 2025, surpassing the benchmark's return of 11.05% [1] - The Fund's performance was driven by strong selection effects, emphasizing a quantitative value discipline focused on fundamental undervaluation and improving momentum [1] Fund Performance - The S&P 500 Index rose 2.7% in Q4 2025 and 17.9% for the full year, while the Russell Midcap Index only increased by 0.2% in Q4 [1] - The Fund's quarterly excess return was 2.82%, primarily attributed to stock selection [1] Investment Focus - Management noted that mid- and small-cap value stocks are trading at more attractive multiples compared to AI-driven large-cap stocks, indicating potential investment opportunities [1] - The Fund is positioned to capitalize on economically sensitive and cash-generative businesses [1] Jazz Pharmaceuticals plc - Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was highlighted as a top performer in the Fund, advancing nearly 30% due to strong third-quarter performance and positive clinical trial results [3] - The stock had a one-month return of 14.88% and traded between $95.49 and $198.00 over the last 52 weeks, closing at approximately $188.97 per share with a market capitalization of about $11.483 billion [2][3] - Jazz Pharmaceuticals was held by 64 hedge fund portfolios at the end of Q4 2025, an increase from 49 in the previous quarter [3]